For the first time in 50 years, a phase 3 randomised, placebo-controlled trial found that an adjuvant therapy improved overall survival in kidney cancer patients.
According to new research, a biomarker signature can predict how well kidney cancer patients will respond to immunotherapy before treatment even starts. This biomarker signature is made up of the number of immune cells in and around kidney tumours, the volume of dead cancer tissue, and mutat
Washington D.C [USA], Oct. 12 (ANI): A recent trial demonstrates that consuming oral tablet Sunitinib for one year reduces the likelihood of cancer returning for kidney cancer patients following removal of the